blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3823669

EP3823669 - COMBINATION OF AN AGONIST ANTI-PD-1 ANTIBODY WITH A GNRH AGONIST OR ANTAGONIST TO TREAT CANCER [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  19.04.2024
Database last updated on 06.07.2024
FormerRequest for examination was made
Status updated on  23.04.2021
FormerThe international publication has been made
Status updated on  03.04.2021
FormerThe application is deemed to be withdrawn
Status updated on  27.11.2020
FormerThe international publication has been made
Status updated on  29.06.2019
Formerunknown
Status updated on  20.03.2019
Most recent event   Tooltip20.04.2024New entry: Despatch of examination report + time limit 
Applicant(s)For all designated states
Debiopharm International SA
Forum "après-demain"
Ch. Messidor 5-7
1002 Lausanne / CH
[2021/21]
Inventor(s)01 / LEJEUNE, Ferdinand
Chemin du Levant 98
1005 Lausanne / CH
02 / GAVILLET, Bruno
430 Route de Pitegny Mourex
01220 Grilly / FR
 [2021/21]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[2021/21]
Application number, filing date18855156.818.12.2018
[2021/21]
WO2018IB01445
Priority number, dateWO2017IB0157618.12.2017         Original published format: PCT/IB2017/001576
[2021/21]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019122998
Date:27.06.2019
Language:EN
[2019/26]
Type: A1 Application with search report 
No.:EP3823669
Date:26.05.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 27.06.2019 takes the place of the publication of the European patent application.
[2021/21]
Search report(s)International search report - published on:EP27.06.2019
ClassificationIPC:A61K39/395, C07K16/28, A61P35/00, A61K38/08
[2021/21]
CPC:
A61K39/3955 (EP,CN); A61K45/06 (EP,CN); A61K38/09 (EP,US);
A61K31/427 (US); A61K31/47 (US); A61P35/00 (EP,CN,US);
C07K16/2818 (EP); A61K2039/876 (EP); C07K2317/75 (EP) (-)
C-Set:
A61K39/3955, A61K2300/00 (CN,EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/21]
TitleGerman:KOMBINATION EINES AGONISTISCHEN ANTI-PD-1-ANTIKÖRPERS MIT GNRH-AGONIST ODER ANTAGONIST ZUR BEHANDLUNG VON KREBS[2021/21]
English:COMBINATION OF AN AGONIST ANTI-PD-1 ANTIBODY WITH A GNRH AGONIST OR ANTAGONIST TO TREAT CANCER[2021/21]
French:COMBINAISON D'UN ANTICORPS AGONISTE ANTI-PD-1 AVEC UN AGONISTE OU ANTAGONISTE GNRH POUR LE TRAITEMENT DU CANCER[2021/21]
Entry into regional phase26.03.2021National basic fee paid 
26.03.2021Designation fee(s) paid 
26.03.2021Examination fee paid 
Examination proceduredeletedDeletion: Application withdrawn by applicant  [2020/53]
21.07.2020Application deemed to be withdrawn, date of legal effect  [2020/53]
26.03.2021Date on which the examining division has become responsible
deletedDeletion: Application deemed to be withdrawn, date of legal effect  [2021/18]
26.03.2021Examination requested  [2021/21]
21.10.2021Amendment by applicant (claims and/or description)
19.04.2024Despatch of a communication from the examining division (Time limit: M04)
Request for further processing for:The application is deemed to be withdrawn due to non-payment of the filing fee
26.03.2021Request for further processing filed
26.03.2021Full payment received (date of receipt of payment)
Request granted
08.04.2021Decision despatched
The application is deemed to be withdrawn due to non-payment of the examination fee
26.03.2021Request for further processing filed
26.03.2021Full payment received (date of receipt of payment)
Request granted
08.04.2021Decision despatched
26.03.2021Request for further processing filed
26.03.2021Full payment received (date of receipt of payment)
Request granted
08.04.2021Decision despatched
The application is deemed to be withdrawn due to non-payment of designation fees
TR, SM, SK, SI, SE, RS, RO, PT, PL, NO, NL, MT, MK, MC, LV, LU, LT, IT, IS, IE, HU, HR, GR, GB, FR, FI, ES, EE, DK, DE, CZ, CY, CH, BG, BE, AT, AL
26.03.2021Request for further processing filed
26.03.2021Full payment received (date of receipt of payment)
Request granted
08.04.2021Decision despatched
26.03.2021Request for further processing filed
26.03.2021Full payment received (date of receipt of payment)
Request granted
08.04.2021Decision despatched
Fees paidRenewal fee
26.03.2021Renewal fee patent year 03
27.12.2021Renewal fee patent year 04
27.12.2022Renewal fee patent year 05
27.12.2023Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
11.01.202103   M06   Fee paid on   26.03.2021
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]WO2015200828  (H LEE MOFFIT CANCER CT AND RES INST INC [US], et al) [X] 1-5,13,14,22-27,35,36 * page 2, line 18 - page 3, line 8 * * examples 1,2 * * claims 1-3,10-15 *;
 [YA]WO2016176504  (BRISTOL MYERS SQUIBB CO [US]) [Y] 1-20,22-42 * the whole document * [A] 21,43;
 [X]WO2017214562  (WISCONSIN ALUMNI RES FOUND [US]) [X] 1,5,7,11,12,18,22,23,27,29,33,34,40 * paragraph [0011] * * examples 6,7 *;
 [YA]  - LIMONTA P ET AL, "GnRH receptors in cancer: From cell biology to novel targeted therapeutic strategies", ENDOCRINE REVIEWS, THE ENDOCRINE SOCIETY, US, (20121001), vol. 33, no. 5, doi:10.1210/ER.2012-1014, ISSN 0163-769X, pages 784 - 811, XP009167657 [Y] 1-20,22-42 * page 792; table 3 * * page 795, column 2, paragraph 3 - page 797, column 2, paragraph 2 * * page 788; table 2 * [A] 21,43

DOI:   http://dx.doi.org/10.1210/er.2012-1014
 [A]  - SUMIT K. SUBUDHI ET AL, "Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, US, (20161003), vol. 113, no. 42, doi:10.1073/pnas.1611421113, ISSN 0027-8424, pages 11919 - 11924, XP055587842 [A] 1-43 * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.1611421113
 [XPI]  - Bachem, "Melanoma Peptides", Peptide Trends, (20181201), pages 1 - 5, URL: https://www.bachem.com/service-support/newsletter/peptide-trends-december-2018/, (20190513), XP055587861 [XP] 1,22,23 * page 4 * [I] 2-21,24-43
 [XPI]  - Thierry Lesimple, "debio 8200-imm-101", Annuaire des essais cliniques, (20180623), URL: https://www.pole-cancerologie-bretagne.fr/newsletter/items/382.html, (20190513), XP055587974 [XP] 1,22,23 * the whole document * [I] 1-21,24-43
 [A]  - DANIEL Y. WANG ET AL, "Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma", CANCER IMMUNOLOGY RESEARCH, US, (20170410), vol. 5, no. 5, doi:10.1158/2326-6066.CIR-16-0287, ISSN 2326-6066, pages 357 - 362, XP055588830 [A] 1-43

DOI:   http://dx.doi.org/10.1158/2326-6066.CIR-16-0287
by applicant   - LEACH et al., Science, (19960000), vol. 271, pages 1734 - 1736
    - LINSLEY et al., Immunity, (19940000), vol. 1, pages 793 - 801
    - RUDD et al., Immunol. Rev., (20090000), vol. 229, pages 12 - 26
    - SCHNEIDER et al., Science, (20060000), vol. 313, pages 1972 - 1975
    - TIVOL et al., Immunity, (19950000), vol. 3, pages 541 - 547
    - WATERHOUSE et al., Science, (19950000), vol. 270, pages 985 - 988
    - PHAN et al., Proc. Natl. Acad. Sci. USA, (20030000), vol. 100, pages 8372 - 8377
    - SCHADENDORF et al., J. Clin. Oncol., (20150000), vol. 33, pages 1889 - 1894
    - PARRY et al., Mol. Cell. Biol., (20050000), vol. 25, pages 9543 - 9553
    - WING et al., Science, (20080000), vol. 322, pages 271 - 275
    - PEGGS et al., J. Exp. Med., (20090000), vol. 206, pages 1717 - 1725
    - DONG et al., Nat. Med., (19990000), vol. 5, pages 1365 - 1369
    - LATCHMAN et al., Nat. Immunol., (20010000), pages 261 - 268
    - TSENG et al., J. Exp. Med., (20010000), vol. 193, pages 839 - 846
    - TUMEH et al., Nature, (20140000), vol. 515, pages 568 - 571
    - NISHIMURA et al., Immunity, (19990000), vol. 11, pages 141 - 151
    - Science, (20010000), vol. 291, pages 319 - 322
    - DONG et al., Nat. Med., (20020000), vol. 8, pages 793 - 800
    - ANSELL et al., N. Engl. J. Med., (20150000), vol. 372, pages 311 - 319
    - AMADZADEH et al., Blood, (20090000), vol. 114, pages 1537 - 1544
    - SFANOS et al., Prostate, (20090000), vol. 69, pages 1694 - 1703
    - TOPALIAN et al., N. Engl. J. Med., (20120000), vol. 366, pages 2443 - 2454
    - J. Clin. Oncol., (20140000), vol. 32, pages 1020 - 1030
    - LEJEUNE, Melanoma Res., (20150000), vol. 25, pages 373 - 375
    - WOLCHOK et al., N. Engl. J. Med., (20130000), vol. 369, pages 122 - 133
    - MATSUO et al., Biophys. Biochem. Res. Commun, (19710000), vol. 43, pages 1334 - 1339
    - BURGUS et al., Proc. Natl. Acad. Sci. USA, (19720000), vol. 69, pages 278 - 282
    - COSTA et al., Prog. NeuroEndocrinlmmunology, (19900000), vol. 3, pages 55 - 60
    - BATTICANE et al., Endocrinol., (19910000), vol. 129, pages 277 - 286
    - STANDAERT et al., Biology of Reproduction, (19920000), vol. 46, pages 997 - 1000
    - MARCHETTI et al., Endocrinol., (19890000), vol. 125, pages 1025 - 1036
    - CHEN et al., J. Clin. Endocrin. Metab., (19990000), vol. 84, pages 743 - 750
    - TANRIVERDI et al., Clin. Exp. Immunol., (20050000), vol. 142, pages 103 - 110
    - DIXIT et al., Endocrinol., (20030000), vol. 144, pages 1496 - 1505
    - DIXIT et al., Biology of Reproduction, (20030000), vol. 68, pages 2215 - 2221
    - POLANCZYK et al., J. Immunol., (20040000), vol. 173, pages 2227 - 2230
    - TAI et al., J. Cell. Physiol., (20080000), vol. 214, pages 456 - 64
    - LAMBERT et al., J. Immunol., (20050000), vol. 175, pages 5716 - 5723
    - WOMEN. HO et al., American Journal of Reproductive Immunology, (19950000), vol. 33, pages 243 - 252
    - KISSICK et al., Proc. Natl. Acad. Sci. USA, (20140000), vol. 111, pages 9887 - 9892
    - RODEN et al., J. Immunol., (20040000), vol. 173, pages 6098 - 6108
    - MERCADER et al., Proc. Natl. Acad. Sci. USA, (20010000), vol. 98, no. 25, pages 14565 - 14570
    - SUTHERLAND et al., J. Immunol., (20050000), vol. 175, pages 2741 - 2753
    - SUTHERLAND et al., Clin. Cancer Res., (20080000), vol. 14, pages 1138 - 1149
    - JOHNKE et al., Anticancer Res., (20050000), vol. 25, pages 3159 - 3166
    - AKINS et al., Cancer Res., (20100000), vol. 70, pages 3473 - 3482
    - EISENHAUER, E.A., Eur. J. Cancer, (20090000), vol. 45, pages 228 - 47
    - SEYMOUR, L. et al., "iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics", Lancet Oncol, (20170000), vol. 18, no. 3, pages e143 - e152
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.